Skip to main content

Table 1 The nine GHRL / GHSR polymorphisms examined in the meta-analysis, the number of studies performed in cancer samples and sample sizes

From: Associations between ghrelin and ghrelin receptor polymorphisms and cancer in Caucasian populations: a meta-analysis

   

N studies

   
 

Polymorphism

References

Cancer type

 

Number of

 
 

BC

CRC

EC

NHL

Total

Cases

Controls

Total

1

GHRL 696217

[10-14],[23]

3

1

1

1

6

3,601

6,101

9,702

2

GHRL 4684677

[10-12],[23]

2

1

1

0

4

2,888

4,938

7,826

3

GHRL 27647

[11],[12],[23]

2

2

0

0

4

2,512

3,709

6,221

4

GHRL 26802

[11],[12],[23]

2

1

0

0

3

1,958

2,994

4,952

5

GHRL 2075356

[11],[12],[23]

2

1

0

0

3

1,941

2,972

4,913

6

GHRL 35684

[11],[13],[23]

1

1

0

1

3

2,144

3,480

5,624

7

GHRL 35683

[12],[23]

1

2

0

0

3

1,864

1,949

3,813

8

GHSR 495225

[11],[14],[23]

2

1

0

0

3

2,350

3,370

5,720

9

GHSR 572169

[11],[14],[23]

2

1

0

0

3

2,378

3,414

5,792

  1. Studies have examined ghrelin gene (GHRL) or ghrelin receptor gene (GHSR) polymorphisms in breast cancer (BC); colorectal cancer (CRC); esophageal cancer (EC); and Non-Hodgkin’s Lymphoma (NHL) [10-14],[23].
  2. SNPs in bold were examined in more detail in the current study.